Oncology News

Treatment with transarterial chemoembolization and Nexavar improved progression-free survival compared with transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma, according to a study published in Gut.

Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according to data presented at the American Society of Hematology meeting.

The GALAD score was superior to individual serum markers in detecting hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, according to a case-control study published in Clinical Gastroenterology and Hepatology Journal.

A combination of atezolizumab and bevacizumab conferred statistically significant and clinically meaningful improvements in PFS and OS compared with sorafenib among patients with unresectable hepatocellular carcinoma, according to results of the randomized phase 3 IMbrave150 study presented at European Society for Medical Oncology Asia Congress.

The FDA granted priority review to pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, according to a press release from the agent’s manufacturer.

BOSTON — In this exclusive video from The Liver Meeting 2019, Naga P. Chalasani, MD, from the Indiana University School of Medicine, discusses the accuracy of combined methylated DNA and protein markers for early-stage detection of hepatocellular carcinoma.

Chemotherapy combined with hepatic arterial infusion of floxuridine or with selective internal radiotherapy induced antitumor activity among patients with unresectable intrahepatic cholangiocarcinoma, according to results of separate phase 2 studies published in JAMA Oncology.

Can-Fite BioPharma announced the initiation of a compassionate use program for Namodenoson to treat patients with hepatocellular carcinoma, according to a press release.

SAN ANTONIO — In this exclusive video from the National Liver Conference 2019, Stephen A. Harrison, MD, medical director of Pinnacle Clinical Research in San Antonio, provides an overview of the topics discussed at the meeting ranging from nonalcoholic steatohepatitis to hepatitis B to liver cancer.

Combination treatment with Tecentriq and Avastin for unresectable hepatocellular carcinoma in patients without prior systemic therapy demonstrated clinically meaningful improvements in both overall and progression-free survival compared with Nexavar, according to a press release from Genentech.